InvestSMART

PharmAust Limited (ASX: PAA) - Announcements

Current share price for PAA : $0.230 0.015 (6.98%)+

ASX company news and announcements for PharmAust Limited (PAA) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All PharmAust Limited (PAA) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than PharmAust Limited (PAA), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for PharmAust Limited (PAA)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
- Change of Director's Interest Notice x 3 16 Mar 2018 6:19PM $0.056 $0.230 risen by 310.71%
- Appendix 3B & s708 notice 16 Mar 2018 5:59PM $0.056 $0.230 risen by 310.71%
- Collaboration with Olivia Newton-John Cancer Research Inst 14 Mar 2018 8:24AM $0.057 $0.230 risen by 303.51%
- Appendix 4D and Half Yearly Report & Accounts 28 Feb 2018 7:56PM $0.057 $0.230 risen by 303.51%
- PharmAust receives $354k R&D Tax Incentive Refund 28 Feb 2018 10:45AM $0.056 $0.230 risen by 310.71%
- Results of General Meeting 26 Feb 2018 6:00PM $0.055 $0.230 risen by 318.18%
- Appendix 4C - Quarterly Report & Shareholders Update 31 Jan 2018 9:11AM $0.069 $0.230 risen by 233.33%
- Monepantel reformulation successfully improves dose & taste 30 Jan 2018 10:52AM $0.074 $0.230 risen by 210.81%
- Notice of General Meeting/Proxy Form 29 Jan 2018 8:26AM $0.068 $0.230 risen by 238.24%
- Epichem Awarded One Year Contract Extension from DNDi 18 Jan 2018 9:56AM $0.066 $0.230 risen by 248.48%
- International Vet Cancer Specialist Joins PAA Advisory Board 18 Dec 2017 10:34AM $0.053 $0.230 risen by 333.96%
- Appendix 3B & s708 notice 14 Dec 2017 10:37AM $0.049 $0.230 risen by 369.39%
- Phase II Dog Lymphoma Trial Confirms MPL Clinical Benefit 13 Dec 2017 8:24AM $0.047 $0.230 risen by 389.36%
- PharmAust Raises $1.873m via an Oversubscribed Placement 6 Dec 2017 9:45AM $0.049 $0.230 risen by 369.39%
- Trading Halt 1 Dec 2017 4:35PM $0.049 $0.230 risen by 369.39%
- Results of Annual General Meeting 29 Nov 2017 2:30PM $0.052 $0.230 risen by 342.31%
- PharmAust AGM Presentation 29 Nov 2017 1:47PM $0.053 $0.230 risen by 333.96%
- PharmAust Launches New Corporate Website 29 Nov 2017 10:29AM $0.051 $0.230 risen by 350.98%
- New MPL analogues show greater anti-cancer activity 23 Nov 2017 9:55AM $0.050 $0.230 risen by 360%
- New drugs patented for cancer in USA 16 Nov 2017 8:31AM $0.049 $0.230 risen by 369.39%
- Epichem Update - progress on milestones and revenue targets 1 Nov 2017 9:21AM $0.050 $0.230 risen by 360%
- Notice of Annual General Meeting/Proxy Form 27 Oct 2017 8:15AM $0.050 $0.230 risen by 360%
- Appendix 4C - Quarterly Report & Brief Company Update 26 Oct 2017 5:57PM $0.050 $0.230 risen by 360%
- Monepantel reformulation project continues to progress 17 Oct 2017 10:10AM $0.054 $0.230 risen by 325.93%
- New patent secured in US for non-cancer applications 10 Oct 2017 8:17AM $0.050 $0.230 risen by 360%

476 - 500 of 796 results

Page 20 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.